Company Profile

DISHMAN CARBOGEN AMCIS LTD.

NSE : DCALBSE : 540701ISIN CODE : INE385W01011Industry : Pharmaceuticals & DrugsHouse : Dishman Pharma
BSE245.300 (0 % )
PREV CLOSE (Rs.) 245.30
OPEN PRICE (Rs.) 247.80
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 46822
TODAY'S LOW / HIGH (Rs.)241.05 247.85
52 WK LOW / HIGH (Rs.)102.55 259.5
NSE245.10 -0.2 (-0.08 % )
PREV CLOSE(Rs.) 245.30
OPEN PRICE (Rs.) 245.10
BID PRICE (QTY) 245.10 (271 )
OFFER PRICE (QTY) 245.30 (70 )
VOLUME 1009
TODAY'S LOW / HIGH(Rs.) 245.10 245.10
52 WK LOW / HIGH (Rs.)102.5 259.7

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.00
TTM EPS (Rs.) -11.85
P/E Ratio 0.00
Book Value (Rs.) 295.60
Face Value (Rs.) 2
MCap (Rs. in Mn) 38458.89
Price/Earning (TTM) -88.74
Price/Sales (TTM) 14.00
Price/Book (MRQ) 0.83
PAT Margin (%) -111.92
ROCE (%) -2.55
Incorporation Year : 2007

Management Info :

Janmejay R Vyas - Chairman Arpit J Vyas - Managing Director

Registered Office :

Address : Dishman Corporate House,Lscon-bopal Road,Ambli,
Ahmedabad,
Gujarat-380058

Phone : 02717 420102/124

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
28Oct10-28-2021$ Announcement under Regulation 30 (LODR)-Press Release / Media Release Announcement under Regulati
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that Company's wholly owned subsidiary namely CARBOGEN AMCIS AG., Switzerland has successfully completed the U.S. Food and Drug Administration (FDA) Inspection of its site in Aarau, Switzerland. In this regard, please find enclosed herewith Press Release on the captioned subject.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disc..
28Oct10-28-2021$Dishman Carbogen Amcis informs about press release Dishman Carbogen Amcis infor
Dishman Carbogen Amcis has informed that the Company's wholly owned subsidiary namely CARBOGEN AMCIS SAS, France, announces the release of a new batch for clinical trials of AGuIX Drug Product for NH TherAguix, a clinical stage company developing innovative nano medicine for the treatment of cancer. In this regard, it enclosed Press Release.

The above information is a part of company’s filings submitted to BSE.

Dishman Carbogen Amcis has informed that the Company's wholly o..
21Oct10-21-2021$Dishman Carbogen Amcis planning to invest $50 million in France to set up new facility Dishman Carbogen Amcis plann

Dishman Carbogen Amcis (DCAL) is planning to invest $ 50 million in France to set up a new facility for manufacturing formulated products, mainly in the form of parenterals. The new facility would begin commercial production from January 2023 with two manufacturing lines.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Dishman Carbogen Amcis (DCAL) is planning to invest $ 50 millio..
21Oct10-21-2021$ Board Meeting Intimation for Consideration Of Un-Audited Financial Result For The Second Quarter And Half Year Ended 30Th September, 2021 Board Meeting Intimation fo
Dishman Carbogen Amcis Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2021 ,inter alia, to consider and approve Un-Audited Financial Result For The Second Quarter and Half year Ended 30th September, 2021
Dishman Carbogen Amcis Ltdhas informed BSE that the meeting of..
21Oct10-21-2021$Dishman Carbogen Amcis trades higher on planning to invest $50 million in France to set up new facility Dishman Carbogen Amcis trade

Dishman Carbogen Amcis is currently trading at Rs. 217.15, up by 3.90 points or 1.83% from its previous closing of Rs. 213.25 on the BSE.

The scrip opened at Rs. 219.95 and has touched a high and low of Rs. 219.95 and Rs. 215.40 respectively. So far 24200 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 259.50 on 07-Oct-2021 and a 52 week low of Rs. 102.55 on 25-Mar-2021.

Last one week high and low of the scrip stood at Rs. 239.40 and Rs. 210.20 respectively. The current market cap of the company is Rs. 3410.82 crore.

The promoters holding in the company stood at 59.32%, while Institutions and Non-Institutions held 12.66% and 28.01% respectively.

Dishman Carbogen Amcis (DCAL) is planning to invest $50 million in France to set up a new facility for manufacturing formulated products, mainly in the form of parenterals. The new facility would begin commercial production from January 2023 with two manufacturing lines.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Dishman Carbogen Amcis is currently trading at Rs. 217.15, up b..
Financials More
Rs. in Millions
QTR Sep 21 ANNUAL 21
Net Profit-28.1000000000001-2328.1
Gross Profit -45.5000000000001 -1686.9
Operating Profit 421.586.9000000000001
Net Sales 841.52080.1
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 19028.25 (1.58%)
M.Cap ( in Cr)
39806.42
Divi's Lab (BSE)
 4676.00 (1.11%)
M.Cap ( in Cr)
122771.25
Torrent Pharma (BSE)
 3100.00 (0.81%)
M.Cap ( in Cr)
52032.53
Sanofi India (BSE)
 7798.00 (0.31%)
M.Cap ( in Cr)
17904.12
Pfizer (BSE)
 4860.90 (0.42%)
M.Cap ( in Cr)
22145.10
Shareholding Pattern More
MUTUAL FUNDS/UTI 6.04 %
PROMOTERS 59.32 %
NON-INSTITUTION 30.13 %
FI/BANKS/INSURANCE 0.01 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes